+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 3Years - 21Years
All Genders
ID05855330

Study of Arginine Replacement Therapy for Children and Young Adults Hospitalized With COVID-19 to Improve Mitochondrial Function

Led by Emory University · Updated on 2026-04-15

21

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating arginine replacement therapy to improve mitochondrial function in children hospitalized with COVID-19. This study focuses on children aged 3 to 21 years who have been admitted for COVID-19 treatment. It aims to better understand the role of arginine deficiency and its impact on inflammation, immune regulation, and disease severity in pediatric COVID-19 cases, including complications like multisystem inflammatory syndrome in children MIS-C and Long Covid. Participants will be randomly assigned to one of three groups receiving different doses of arginine a loading dose plus standard dose, a standard dose alone, or a low dose. Arginine will be infused intravenously three times a day for five days or until discharge, whichever comes first. Doses are adjusted by weight and infused over 30 to 60 minutes, depending on tolerance. During the study, participants will undergo assessments at baseline and after five days to measure changes in mitochondrial function and various biological markers such as amino acids, arginase-1 activity, immune cells, cytokines, and secretory phospholipase levels. The research team will monitor safety and treatment effects throughout the hospital stay. The study will last approximately five days per participant, focusing on short-term changes related to arginine therapy.

CONDITIONS

Brief Title

Arginine Replacement Therapy in COVID-19

Research Team

C

Claudia R. Morris, MD

D

Dunia Hatabah, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here